GNPDA1 Inhibitors
Inhibitors of GNPDA1 function through a variety of mechanisms that disrupt the enzyme's activity or the availability of its substrates and cofactors. Some inhibitors structurally mimic glucose or glutamine, the substrates of GNPDA1, and by competing with them, they prevent the normal interaction with the enzyme's active site. This competitive inhibition effectively reduces the enzyme's ability to catalyze the deamination of glucosamine-6-phosphate. Other inhibitors interfere with the cellular metabolic pathways that generate the substrates or cofactors necessary for GNPDA1's activity. For instance, inhibition of glycosylation processes or protein synthesis can indirectly lead to a decrease in GNPDA1 functionality by altering the enzyme's maturation or stability. Additionally, compounds that impact the cellular uptake of glucose or the synthesis of nucleotides can indirectly diminish the activity of GNPDA1 by limiting the production of glucose-6-phosphate and other metabolites crucial for its enzymatic action.
Moreover, certain molecules indirectly influence GNPDA1 activity by modulating the cellular environment in which the enzyme operates. For instance, by inhibiting enzymes that are key to maintaining membrane lipid composition, some inhibitors can alter membrane dynamics, which can, in turn, affect the activity of membrane-associated enzymes like GNPDA1. Other compounds may alter intracellular pH levels or disrupt lysosomal function, which indirectly affects the glycosylation patterns within the cell and consequently, the functionality of GNPDA1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
This glucose analog acts as a competitive inhibitor of glucose metabolism. By mimicking glucose, it inhibits GNPDA1, which requires glucose-6-phosphate as a substrate for deamination. | ||||||
6-Diazo-5-oxo-L-norleucine | 157-03-9 | sc-227078 sc-227078A sc-227078B sc-227078C | 5 mg 25 mg 100 mg 250 mg | $82.00 $285.00 $908.00 $2152.00 | ||
An analog of glutamine that inhibits glutamine-utilizing enzymes. It indirectly inhibits GNPDA1 by depleting glutamine, which is necessary for the synthesis of glucosamine-6-phosphate. | ||||||
Manoalide | 75088-80-1 | sc-200733 | 1 mg | $264.00 | 9 | |
This sesterterpenoid inhibits phospholipase A2, disrupting cellular membrane composition and indirectly affecting GNPDA1 activity by altering substrate availability. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $163.00 $316.00 | 436 | |
Inhibits protein synthesis by causing premature chain termination during translation. It indirectly inhibits GNPDA1 by reducing the overall protein synthesis, including GNPDA1 itself. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
An antimetabolite that inhibits dihydrofolate reductase, leading to reduced purine synthesis and indirectly affecting GNPDA1 by altering nucleotide availability for enzyme function. | ||||||
Phloretin | 60-82-2 | sc-3548 sc-3548A | 200 mg 1 g | $63.00 $250.00 | 13 | |
A dihydrochalcone that inhibits various glucose transporters, thereby reducing glucose uptake and indirectly inhibiting GNPDA1 by decreasing the substrate pool for glycolysis and its byproducts. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
An inhibitor of N-linked glycosylation, indirectly affecting GNPDA1 by disrupting the glycosylation status of proteins, which can alter enzyme functionality, including GNPDA1. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
A pyrimidine analog that inhibits thymidylate synthase, leading to decreased DNA synthesis and indirectly inhibiting GNPDA1 by lowering cell proliferation and enzyme demand. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Affects lysosomal pH and can inhibit glycosylation processes. Indirectly inhibits GNPDA1 by affecting the cellular environment and glycosylation patterns. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
An inhibitor of eukaryotic protein synthesis by interfering with the translocation step on ribosomes. It indirectly inhibits GNPDA1 by reducing the synthesis of the enzyme itself. | ||||||